Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
N/A
2(50.0%)
4Total
Phase 1(2)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05710094Phase 1Completed

Safety and Tolerability of Single and Multiple Doses of SoftOx Biofilm Eradicator (SBE) in Chronic Leg Wounds

Role: lead

NCT05188638Phase 1Completed

Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects

Role: lead

NCT04771819Not ApplicableCompleted

Safety and Performance of SWIS in Superficial Wounds

Role: lead

NCT03742284Not ApplicableUnknown

Safety and Performance of SoftOx Wound Irrigation Solution (SWIS) in Acute Wounds

Role: lead

All 4 trials loaded